- Global Pharma News & Resources
13-Jun-2022 - 15-Jun-2022

2nd Annual Oligonucleotides for CNS Summit

  • Location:
    • Hilton Boston Logan Airport
    • One Hotel Drive
    • Boston
    • Massachusetts
    • 02128
    • United States
  • View on a map

With Biogen investing millions in Ionis' efforts to weaponize ASOs against SMA, Stoke Therapeutics collaborating with Acadia Pharmaceuticals to supercharge the development of RNA-Based treatments for genetic neurodevelopmental diseases and the global oligonucleotide therapeutics market set to experience unprecedented growth, there’s never been a more opportune moment for biopharma to expand their oligonucleotide pipelines into the untapped potential of the CNS.

Dedicated to providing you with the insights you need to create clinically defining oligonucleotide therapeutics, the 2nd Oligonucleotides for CNS Summit will unite a multinational faculty of experts from Eli Lilly, Roche, Biogen, Alnylam, Servier, Stoke Therapeutics and more to divulge the critical insights you need to accelerate your oligonucleotide therapeutic development against Alzheimer’s, Huntington’s, Glioblastoma and more!

From learning how to manipulate oligonucleotide chemistry to maximize therapeutic potency to more effectively collaborating with CROs/CMOs to manufacture therapies in line with regulatory standards and exploring antibodies, small Molecules & nanoparticles for movement across the blood brain barrier, this focused industry forum will give you the chance to gain back-to-back insights on the science propelling oligonucleotide therapeutics forward in 2022.

As industry turn their heads towards the CNS in a bid to capitalize on its strategic opportunity,  join 150+ ASO and RNA-Based therapeutic experts this June at this unique forum for a dynamic mix of formal presentations, audience discussions, panel discussions and organized networking and leave with the expertise your team needs to optimize your oligonucleotides approach in the CNS this year.